Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

• Results Overview

  Dupilumab with topical steroids significantly improved eczema symptoms in adults who couldn't use or didn't respond to ciclosporin A, with about 60% of patients showing major improvement compared to 30% on placebo.

• Study Summary

  Num Participants:

  318

  Study Type:

  Rct

  Control Group:

  Placebo + Topical Corticosteroids

  Efficacy End Points Treatment:

  {'EASI-75': 62.6}

  Efficacy End Points Control:

  {'EASI-75': 29.6}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Conjunctivitis	Low

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Skin Infections	Medium